In total, the company has lost $165.5 million in 2019.
Alkermes CEO Richard Pops said during an earnings call that the layoffs will affect research and development staff, but offered no specifics about where the cuts would take place, according to Boston Business Journal.
Mr. Pops told the Boston Business Journal the layoffs are part of an effort to “re-baseline” the company’s expense profile and to help it pursue business development opportunities and prepare for the potential commercialization of its forthcoming depression drug.
Earlier this year, the FDA rejected Alkermes’ opioid-based antidepressant, which analysts predicted could have generated more than $1 billion in annual sales.
The company’s current business plans revolve around ALKS 3831, a drug designed to treat schizophrenia that was expected to be submitted to the FDA for approval in mid-2019 but was delayed while the company expands the application to include bipolar disorder.
Alkermes could also earn $27 million from Biogen in a deal for the multiple sclerosis drug, Vumerity, which the FDA is expected to approve or reject by the end of the year.
Read the full article here.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Cheating scandal prompts California to invalidate pharmacist test scores
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.